… patients are underrepresented in clinical trials that have evaluated oral anticoagulation in
patients with atrial fibrillation (… impact of oral anticoagulation in patients with AF age ≥90 years. …

… nonvitamin K antagonist oral anticoagulant (NOACs) and warfarin in patients with atrial
fibrillation … recommend the use of nonvitamin K antagonist oral anticoagulants (NOACs) as …

… Atrial fibrillation (AF) prevalence and its risk of stroke rise with ageing. We aimed to … (OACs),
either warfarin or nonvitamin K antagonist oral anticoagulants (NOACs), in AF patients with …

… and safety of non-vitamin K oral antagonists (NOACs) vs. vitamin K antagonists (VKAs) in
elderly patients with atrial fibrillation (AF) and indirectly compare NOACs in this population. …

… The need for anticoagulant therapy in atrial fibrillation (AF) patients with thrombocytopenia
is increasing in our aging society [1, 2]. Thrombocytopenia is associated with an increased …

… Background: Current guidelines do not suggest in which groups of patients with atrial
fibrillation (AF) individual non-vitamin K antagonist oral anticoagulants (NOACs) should be used …

… of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J
… . Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. Ther Adv …

… atrial fibrillation (AF) and obesity has steadily increased. Nonvitamin K antagonist oral
anticoagulants (… ) for long-term stroke prevention in patients with nonvalvular AF. There are still …

… The introduction of the nonvitamin K antagonist oral anticoagulants (NOACs) has provided
an equally effective, safer, and more convenient choice than warfarin. NOACs may overcome …

… the effectiveness and safety outcomes between nonvitamin K antagonist oral anticoagulants
(NOACs) and vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients with a history of …